Nottingham Advisors Inc. Sells 87,938 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Nottingham Advisors Inc. cut its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 47.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 97,828 shares of the biopharmaceutical company's stock after selling 87,938 shares during the quarter. Nottingham Advisors Inc. owned 0.06% of Ocular Therapeutix worth $835,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its stake in Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company's stock valued at $9,661,000 after purchasing an additional 660,080 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Ocular Therapeutix by 11.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 130,202 shares of the biopharmaceutical company's stock valued at $1,133,000 after acquiring an additional 13,238 shares during the last quarter. FMR LLC boosted its stake in shares of Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company's stock worth $3,779,000 after acquiring an additional 428,335 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Ocular Therapeutix in the 3rd quarter worth $544,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Ocular Therapeutix during the third quarter valued at $2,047,000. Institutional investors own 59.21% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares of the company's stock, valued at $1,510,797.64. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,895 shares of company stock worth $283,772. Insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on OCUL. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 11th. They set a "buy" rating and a $15.00 price objective on the stock. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada initiated coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Ocular Therapeutix has a consensus rating of "Moderate Buy" and a consensus price target of $16.38.

Ocular Therapeutix Stock Down 9.1 %

Shares of Ocular Therapeutix stock traded down $0.64 on Friday, hitting $6.36. 2,891,880 shares of the company traded hands, compared to its average volume of 1,560,783. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.78. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The company has a market cap of $1.01 billion, a PE ratio of -4.82 and a beta of 1.49. The company has a 50-day moving average price of $7.42 and a 200 day moving average price of $8.69.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Sell-side analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.